Skip to main content

Bifidobacterium longum Subspecies infantis (B. infantis) in Pediatric Nutrition: Current State of Knowledge

  • 2020-05-28
  • Nutrients 12(6)
    • M. Chichlowski
    • N. Shah
    • J. Wampler
    • Steven S. Wu
    • J. Vanderhoof

Abstract

Abstract: Since originally isolated in 1899, the genus Bifidobacterium has been demonstrated to predominate in the gut microbiota of breastfed infants and to benefit the host by accelerating maturation of the immune response, balancing the immune system to suppress inflammation, improving intestinal barrier function, and increasing acetate production. In particular, Bifidobacterium longum subspecies infantis (B. infantis) is well adapted to the infant gut and has co-evolved with the mother-infant dyad and gut microbiome, in part due to its ability to consume complex carbohydrates found in human milk. B. infantis and its human host have a symbiotic relationship that protects the preterm or term neonate and nourishes a healthy gut microbiota prior to weaning. To provide benefits associated with B. infantis to all infants, a number of commercialized strains have been developed over the past decades. As new ingredients become available, safety and suitability must be assessed in preclinical and clinical studies. Consideration of the full clinical evidence for B. infantis use in pediatric nutrition is critical to better understand its potential impacts on infant health and development. Herein we summarize the recent clinical studies utilizing select strains of commercialized B. infantis.

Keywords: B. infantis; Bifidobacterium longum subspecies infantis; acetate; gut health; human milk oligosaccharides; inflammation; microbiome; pediatric nutrition; probiotics; short chain fatty acids.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium infantisAccelerated Immune Response MaturationBeneficial
Moderate
Bifidobacterium infantisImproved Intestinal Barrier FunctionBeneficial
Moderate
Bifidobacterium infantisIncreased Production of AcetateBeneficial
Moderate
Bifidobacterium infantisReduced InflammationBeneficial
Moderate
Bifidobacterium infantis BI02Accelerated Immune Response MaturationBeneficial
Moderate
Bifidobacterium infantis BI02Improved Intestinal Barrier FunctionBeneficial
Moderate
Bifidobacterium infantis BI02Increased Production of AcetateBeneficial
Moderate
Bifidobacterium infantis BI02Reduced Inflammatory ResponseBeneficial
Moderate
Bifidobacterium infantis SD-6720Accelerated Immune Response MaturationBeneficial
Moderate
Bifidobacterium infantis SD-6720Improved Intestinal Barrier FunctionBeneficial
Moderate
Bifidobacterium infantis SD-6720Increased Production of AcetateBeneficial
Moderate
Bifidobacterium infantis SD-6720Reduced InflammationBeneficial
Moderate
Bifidobacterium longum subsp. infantisAccelerated Immune Response MaturationBeneficial
Moderate
Bifidobacterium longum subsp. infantisImproved Intestinal Barrier FunctionBeneficial
Moderate
Bifidobacterium longum subsp. infantisIncreased Production of AcetateBeneficial
Moderate
Bifidobacterium longum subsp. infantisReduced InflammationBeneficial
Moderate
Bifidobacterium longum subsp. infantis M-63Accelerated Immune Response MaturationBeneficial
Moderate
Bifidobacterium longum subsp. infantis M-63Improved Intestinal Barrier FunctionBeneficial
Moderate
Bifidobacterium longum subsp. infantis M-63Increased Production of AcetateBeneficial
Moderate
Bifidobacterium longum subsp. infantis M-63Reduced Inflammatory ResponseBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.